Home
Sites
Company Introduction
Contact Us
Project&Products
18 Aug, 2023
Jan, 2022
Virtue and Labtest Made an Impressive Debut at the 2023 AACC
8 Sep, 2023
Labtest Debuted Its Latest CLIA Solution at the 2023 CBPC/ML
diagnostic systems
in vitro
next generation
Virtue and Revvity Ink Exclusive Global Distribution Agreement
focused on enabling innovative
Virtue Took on National Standard Substance Calibration Projects
13 Dec, 2023
new Industrial platform
1 Sep, 2022
Creating a
26 Oct, 2022
Creating a new Industrial platform
focused on enabling innovative next generation
in vitro diagnostic systems
Virtue establishes Southeast Asia's largest IVD Manufacturer
1 Apr,2023
Virtue Showcased QSight 420MD at the 2023 NCLM
Virtue Diagnostics closes $100 million Series B Funding
Virtue Honored with the 2023 Best IVD Enterprise Award
Virtue Announced Acquisition of Labtest Diagnostics in Brazil
5 Mar, 2024
27 Jul, 2023
3 Aug, 2023
Virtue Showcased Clinical MS Technology at 2022 CACLP
Accelerate clinical diagnostics innovation
for a healthier world
al_PhysicalPresence
About / 01
al_CompanyVideo
Our Vision
al_Focus
About / 02
About / 03
Focus
al_CollaborativeRD
Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases. Our goal is to utilize our diverse technology platforms to provide clinical solutions for patients at all disease stages including early screening, initial diagnosis, treatment monitoring and minimal residual disease management.
About / 04
Create a leading innovative global diagnostic company
by leveraging diverse technology platforms
through internal development and external collaboration.
al_TechnologyPlatforms
Our Mission
Technology
Platforms
Virtue Suzhou Site Grand Openning
Physical
Presence
VIRTUEDX Company Video
al_WhoWeAre
Virtue Diagnostics has built a team of experienced leaders around specific technology platforms coupled with automated workstation capabilities for chemiluminescence, clinical mass spectrometry, multi-label pathology, single cell technology and other molecular biology technologies.
al_Mission
Virtue Diagnostics’ physical presence is split between Singapore, Suzhou and Beijing China. Our R&D is headquartered in Singapore, manufacturing in Suzhou, and our CRO in Beijing. In 2020, we opened a highly advanced, 1000 m² R&D center, that was designed to incorporate diverse technical capabilities with a strong desire to foster collaborative development. Our new 6000 m² diagnostic instrument and reagent manufacturing site at Biobay in the Suzhou Industrial Park, is open and has begun instrument manufacturing. Our 500 m² CRO in Beijing is focused cancer detection using next generation Pathology platforms.
Collaborative
R&D
Virtue Diagnostics has adopted a new collaborative model, which establishes a complete industrial chain from innovative research and development to clinical trials, clinical applications, and large-scale industrialization. It serves the world's advanced diagnostic technologies and provides solutions to China and other emerging markets.
Who We Are
News
Country / Region
Products
Investors
Careers
al_Hematology
Thoughtput
Photometric 360T/H and ISE 180T/H
Sample Capacity
100
Reagent Position
100
Dual Source
HSID (Hot Source Induced Desolvation)
Laminar Flow Ion Guide
UniField Detector
As in mass spectrometry, the equipment for mIHC was designed for research labs. This equipment is exceedingly expensive and has not been designed for hundreds or thousands of clinical samples. Based on our partnership with a leading mIHC service laboratory in China, we will develop a vastly lower cost IHC multiplex cell analysis platforms specifically designed for the clinical market. We also see exceptional opportunity to bring solutions for single cell analysis, digital/next generation pathology for treatment involving checkpoint inhibitors and immune modulators.
VERCENTRA CS-3000
Audmax 360
QSight 420MD
Advances in genomics and proteomics has enabled researchers to uncover the molecular events that are the underlying basis for developing a disease. Often a combination of genetic changes either through spontaneous mutations or inheritance, lead to this disease state. Identifying and understanding these molecular changes has driven clinicians and researchers to diagnose and treat disease in a novel way.
Pathology, the discipline of physical identification of disease within tissue or cells, has now become the center point to ascertain exactly what is problem and if or how it may be treated. Visualization of excised tissue or isolated circulating tumor cells involves multiplex immunohistochemistry or mIHC. mIHC, involves using highly specific stains to identify molecular markers that are disease specific. Gone are the days of labeling cancer based on the organ or site of identification. Today, the underlying genetic changes that leads to the disease is identified and appropriate treatments are recommended.
Biochemistry
Multiplex Pathology
ObjAreasA
al_Others
Thoughtput
120T/H
Sample Capacity
24
Reagent Position
15
Thoughtput
Photometric 240T/H and ISE 240T/H
Sample Capacity
80
Reagent Position
80
ObjAreasB
Category
3-Part
Thoughtput
40 T/H
Parameters
19
Audmax 240
VERCENTRA CS-1500
ObjAreasC
Chemiluminescence
Aud H3
Blood cell analysis platforms, based on automation, are devices that can rapidly and accurately classify and count blood samples, enhancing laboratory efficiency and reducing human errors. They can simultaneously measure multiple blood cell parameters, such as white blood cell count, red blood cell count, hemoglobin concentration, platelet count, etc., providing comprehensive blood analysis information. Blood cell analysis platforms can be categorized into 3-classification and 5-classification based on whether they further classify white blood cells into lymphocytes, neutrophils, and monocytes.
Hematology
Clinical Mass Spectrometry
Short TAT
Precise
Reagent-saving
Thoughtput
Photometric 800T/H and ISE 460T/H
Sample Capacity
140
Reagent Position
134
Thoughtput
Photometric 180T/H and ISE 360T/H
Sample Capacity
40
Reagent Position
80
SuperFlex
Audmax 800
Although LC-MS has been used for newborn screening globally for many years, its application in specialized diagnostics is subject to higher restrictions. Automated operation, user-friendly software, and pre-packaged reagent kits are crucial for the further promotion of LC-MS. With the maturation and commercialization of the technology, improvements in these aspects will enhance the usability and reliability of the equipment, facilitating broader clinical applications and making it an essential tool in clinical diagnostics.
al_ClinicalMass Spectrometry
Category
5-Part
Thoughtput
60 T/H
Parameters
25+4 research ones
Audmax 180 Evolution
Go to Panovue
Chemiluminescence immunoassay technology is classified into three major platforms based on different luminescence principles: enzyme-linked chemiluminescence, direct chemiluminescence, and electrochemiluminescence. Among them, direct chemiluminescence using acridinium esters as the luminescent label does not require enzymatic catalysis. The system is more stable, and the luminescence in the direct chemiluminescence system is rapid, resulting in shorter time to obtain results. Moreover, acridinium esters, as the luminescent marker, offer significant advantages compared to luminol-based systems, including better control over labeling, lower background signal levels, improved signal-to-noise ratio, absence of intrinsic luminescence, and stable detection results.
Aud H5
Others
Thoughtput
800T/H
Sample Capacity
180
Reagent Position
200
Thoughtput
Photometric 600T/H and ISE 400T/H
Sample Capacity
115
Reagent Position
112
al_Chemiluminescence
VERCENTRA CH-800
Audmax 600
Category
5-Part with autoload
Thoughtput
60 T/H
Parameters
27
al_Biochemistry
Aud H5AL
ObjAreasD
Liquid chromatography-tandem mass spectrometry (LC-MS) is a relatively new technology in the field of clinical diagnostics. Mass spectrometry provides unparalleled sensitivity and specificity for the analysis of metabolites, particularly in the detection of structurally similar small molecules such as vitamins, steroids, and hormones, where it offers significant advantages.
ObjAreasE
Thoughtput
Photometric 400T/H and ISE 400T/H
Sample Capacity
115
Reagent Position
67 on R1 and 45 on R2 disc
Thoughtput
400T/H
Sample Capacity
96
Reagent Position
72
Audmax 400
Category
3-Part
Thoughtput
60 T/H
Parameters
24
VERCENTRA CH-400
al_Products
VERCENTRA HA-30
Biochemical analysis is one of the important analysis platforms frequently used in clinical laboratory testing. It involves analyzing blood or other body fluids to measure various biochemical indicators, such as transaminases, hemoglobin, albumin, total protein, cholesterol, creatinine, glucose, inorganic phosphorus, amylase, calcium, and more. A fully automated biochemical analyzer, as the name suggests, automates the steps of sampling, reagent addition, mixing, incubation, detection, result calculation and display, as well as cleaning during the analysis process. It can completely mimic and replace manual operations. Fully automated biochemical analyzers are sensitive, accurate, and fast, not only improving work efficiency but also reducing subjective errors and enhancing the quality of laboratory testing.
Thoughtput
240T/H
Sample Capacity
96
Reagent Position
24
Investor
[if gte mso 9]>
Normal
0
7.8 磅
0
2
false
false
false
EN-US
ZH-CN
AR-SA
+
BUTTON
Lorem ipsum dolor sit ametes consectetur adipiscing elite.
Contact Us
info@virtuedx.com
Contact Us
Unleash your potential in VIRTUEDX.
Singapore
Explore Open Positions
Brazil
We're building a future where Openness, Collaboration, Integrity, and Innovation are the pillars of success.
China
al_Careers
Indonesia
Open
Collaboration
Integrity
Innovation
Start Your Career
Virtue Suzhou
Virtue South America Manufacrturing Site
Brazil
leading innovative
Labtest
Indonesia
diverse technology platforms
SiteAddA
Kawasan Industri Jababeka tahap 7, Kavling B3B, Desa Wangunharja,
Kecamatan Cikarang Utara, Kabupaten Bekasi 17530 Indonesia
Go to Labtest
al_Indonesia
Virtue Diagnostics Suzhou site is a 6300 m² diagnostic instrument and reagent manufacturing site and clinical laboratory at Biobay in Suzhou Industrial Park. Our state of the art facility is fully equipped and designed with the regulatory requirements for manufacturing clinical diagnostic reagents and instruments for immunoassays, nucleic acid tests and clinical pathology diagnostics.
Singapore R&D Center
11Biopolis Way, Helios L03-10/11 & L08-06/07/08, Singapore
Virtue Singapore
Virtue Diagnostics is a 8000 m² diagnostics instrument and reagent manufacturing site set up in 2022. Through this site, Virtue Diagnostics has the local capability to expand emerging markets in SEA.
by leveraging
SiteAddB
SiteAddD
Our Singapore R&D Hub with 1000 m² focused on Instrument and reagent development on two floors. We have technical expertise is in Mass Spectrometry, Immunoassay and Molecular Diagnostics with over 20 senior scientists in place focused on technological transfer and clinical development
Virtue South East Asia Manufacturing Site
internal development
al_Country
Virtue Indonesia
701, Building B, New Bund World Trade Center III, #11, Dongyu Road 221,
Pudong New Area, Shanghai, 200216
global diagnostic company
Create a
www.panovue.cn
Virtue Shanghai office is located at New Bund area in Shanghai. It's positioned as a China commercial center including sales & marketing functions. Additionally, most of Virtue Diagnostics global supporting functions are loacted in this office.
Building 14, Zone B, Biological Industry Park, No.218 Sangtian Street,
Suzhou Industrial Park, 215127
through
Virtue China Commercial Office
al_Singapore
Virtue Shanghai
Panovue is our leading High Content Pathology CRO and service lab. We have begun the process to productize the business through offering a automated system if off the shelf IVD assay kits. We have begun to build a fully integrated system including staining machine, image analysis and software with registered reagents as IVD kits.
Av. Paulo Ferreira Da Costa, 600, Vista Alegre,
Lagoa Santa – Mg. Cep: 33.240-152. Brasil
SiteAddC
al_China
Virtue China Multiplex Pathology Center and Service Lab
China
al_Brazil
Virtue China Manufacturing and R&D Site
and external collaboration.
L4 Building 1, Yard 5, No. 5 Gaoxin Street, Huilongguan Town, Changping District,
Beijing, 102206
Panovue
Labtest is a leading IVD company in Brazil with more than 50 years history and was acquired by Virtue Diagnostics in 2022. Based on Labtest's full capabilities including R&D, Manufacturing, Selling & Marketing both in reagents and instruments, Virtue Diagnostics is able to build strongest local IVD capabilities in South America to expand emerging markets in LATAM.
Singapore
Go to Panovue
MORE
customerservice.id@virtuedx.com
Copyright © 2023 VIRTUE Diagnostics(Suzhou)Co.,Ltd.
Who we are
Investors
+86 400 600 8133
Others
Focus
China
Chemiluminescence
Collaborative R&D
Hematology
Vision
Careers
Clinical Mass Spectrometry
TOP
Company Video
Global Innovation ● Local Solution
Products
Singapore
Mission
Indonesia
+62 21 89326108
News
+55 0800 031 3411
Physical Presence
Brazil
Country / Region
labtest@labtest.com.br
Biochemistry
Technology Platforms